Drug Trial Radar · NCT05720117
A Study of PYX-201 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
330
Planned (sponsor's estimate)
Start
Mar 14, 2023
Primary completion
Apr 25, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Pyxis Oncology, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Conditions
- Solid Tumor
- Advanced Solid Tumor
Interventions
PYX-201Drug
Antibody-Drug Conjugate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants who Experience a Dose-limiting Toxicity (DLT) in Dose EscalationTime frame: Day 1 to Day 21
- Safety and Tolerability as assessed by adverse event monitoring for participants in Dose EscalationTime frame: Up to approximately 3 years
- Objective Response Rate (ORR) observed in participants in Dose ExpansionTime frame: Up to approximately 2 years
Locations
29 sites in 4 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona · Recruiting
Ronald Reagan UCLA Medical Center
Los Angeles, California · Recruiting
SCRI - HealthOne Denver
Denver, Colorado · Recruiting
SCRI - Florida Cancer Specialists
Sarasota, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
University of Chicago Medicine
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Recruiting
NEXT Dallas
Dallas, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT San Antonio
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Institut Jules Bordet
Brussels, Brussels Capital, Belgium · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Brussels Capital, Belgium · Recruiting
Universitair Ziekenhuis Antwerpen
Edegem, Edegem, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Gent, Belgium · Recruiting
Hospital Universitari Vall d'Hebrón
Barcelona, Barcelona, Spain · Recruiting
START Madrid - Hospital Universitario Fundación Jiménez Díaz
Madrid, Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain · Recruiting
Hospital Universitario HM Sanchinarro
Madrid, Madrid, Spain · Recruiting
Hospital Clínico Universitario de Valencia
Valencia, València, Spain · Recruiting
University College Hospital
London, England, United Kingdom · Recruiting
The Royal Marsden Hospital
London, England, United Kingdom · Recruiting
Sarah Cannon Research Institute London
London, England, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.